US Pharma MarketingThe post First patient dosed in MacroGenics’ Phase I MGC030 trial appeared first on Clinical Trials Arena.
First patient dosed in MacroGenics’ Phase I MGC030 trial
MacroGenics has dosed the first patient in a Phase I study of its investigational therapy, MGC030, for advanced solid tumours. The trial will enrol up to 54 patients in the initial escalation phase. MGC030 is an ADC directed at an undisclosed antigen found on multiple types of solid tumours. Credit: Love Employee/Shutterstock.com. US-based clinical-stage biopharmaceutical company MacroGenics has dosed the first patient in a Phase I study of its investigational therapy, MGC030, for advanced solid tumours. MGC030 is an antibody-drug conjugate (ADC) directed at an undisclosed antigen found on multiple types of solid tumours. LOA and PTSR Model Cretostimogene…
MacroGenics has dosed the first patient in a Phase I study of its investigational therapy, MGC030, for advanced solid tumours.
Source: Clinical Trials Arena